> top > docs > PubMed:22813865 > annotations

PubMed:22813865 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T104 1421-1431 D007238 denotes infarction
T105 1421-1431 D007238 denotes infarction
T106 1463-1478 UBERON:0002435 denotes dorsal striatum
T107 1463-1478 UBERON:0005382 denotes dorsal striatum
T108 1463-1478 UBERON:0005383 denotes dorsal striatum
T111 1487-1495 UBERON:0000210 denotes parietal
T112 1496-1510 UBERON:0002022 denotes insular cortex
T113 1496-1510 UBERON:0034891 denotes insular cortex
T115 1534-1537 Q03701 denotes CBF
T116 1534-1537 PR:O97101 denotes CBF
T117 1534-1537 PR:000005312 denotes CBF
T118 1534-1537 P53569 denotes CBF
T119 1538-1547 MOP:0000569 denotes reduction
T120 1599-1606 CHEBI:52071 denotes dextran
T121 1599-1606 D003911 denotes dextran
T122 1599-1606 D003911 denotes dextran
T123 1620-1623 CHEBI:340824 denotes MMP
T126 1620-1623 CHEBI:59761 denotes MMP
T127 1620-1625 PR:P08253 denotes MMP-2
T128 1620-1625 Q9GLE5 denotes MMP-2
T129 1620-1625 P08253 denotes MMP-2
T130 1620-1625 Q90611 denotes MMP-2
T132 1620-1625 PR:Q8MPP3 denotes MMP-2
T133 1620-1625 P33436 denotes MMP-2
T134 1620-1625 PR:Q90611 denotes MMP-2
T135 1620-1625 PR:P33436 denotes MMP-2
T136 1620-1625 PR:000010479 denotes MMP-2
T137 1620-1625 PR:P33434 denotes MMP-2
T138 1620-1625 P33434 denotes MMP-2
T139 1620-1625 P50757 denotes MMP-2
T131 1620-1625 GO:0004228 denotes MMP-2
T140 1652-1661 SO:0001185 denotes enzymatic
T141 1672-1679 4716 denotes gelatin
T142 1672-1679 D005780 denotes gelatin
T143 1672-1679 CHEBI:5291 denotes gelatin
T146 1709-1712 PR:O04529 denotes MMP
T144 1709-1712 CHEBI:340824 denotes MMP
T147 1709-1712 CHEBI:59761 denotes MMP
T145 1709-1712 GO:0004235 denotes MMP
T148 1713-1722 CHEBI:35222 denotes inhibitor
T149 1723-1729 C078131 denotes GM6001
T150 1723-1729 C078131 denotes GM6001
T151 1723-1729 CHEBI:137236 denotes GM6001
T152 1752-1759 CHEBI:52071 denotes dextran
T153 1752-1759 D003911 denotes dextran
T154 1752-1759 D003911 denotes dextran
T156 1892-1895 UBERON:0000120 denotes BBB
T157 1907-1913 UBERON:0000479 denotes tissue
T158 1914-1924 D007238 denotes infarction
T159 1914-1924 D007238 denotes infarction
T160 1997-2000 UBERON:0000120 denotes BBB
T161 2037-2042 UBERON:6110636 denotes brain
T162 2037-2042 UBERON:0000955 denotes brain
T163 2074-2082 D007511 denotes ischemia
T164 2074-2082 D007511 denotes ischemia
T165 2088-2091 CHEBI:340824 denotes MMP
T168 2088-2091 CHEBI:59761 denotes MMP
T169 2088-2093 PR:P08253 denotes MMP-2
T170 2088-2093 Q9GLE5 denotes MMP-2
T171 2088-2093 P08253 denotes MMP-2
T172 2088-2093 Q90611 denotes MMP-2
T174 2088-2093 PR:Q8MPP3 denotes MMP-2
T175 2088-2093 P33436 denotes MMP-2
T176 2088-2093 PR:Q90611 denotes MMP-2
T177 2088-2093 PR:P33436 denotes MMP-2
T178 2088-2093 PR:000010479 denotes MMP-2
T179 2088-2093 PR:P33434 denotes MMP-2
T180 2088-2093 P33434 denotes MMP-2
T181 2088-2093 P50757 denotes MMP-2
T173 2088-2093 GO:0004228 denotes MMP-2
T182 2129-2132 UBERON:0000120 denotes BBB
T1 28-47 UBERON:0000120 denotes blood brain barrier
T4 59-65 UBERON:0000479 denotes tissue
T5 66-76 D007238 denotes infarction
T6 66-76 D007238 denotes infarction
T7 103-111 D007511 denotes ischemia
T8 103-111 D007511 denotes ischemia
T9 125-130 UBERON:6110636 denotes brain
T10 125-130 UBERON:0000955 denotes brain
T11 140-143 UBERON:0000120 denotes BBB
T12 242-248 PR:Q54JW9 denotes impact
T13 242-248 PR:Q642J4 denotes impact
T14 368-371 UBERON:0000120 denotes BBB
T15 508-511 UBERON:0000120 denotes BBB
T16 544-550 UBERON:0000479 denotes tissue
T17 585-593 D007511 denotes ischemia
T18 585-593 D007511 denotes ischemia
T19 617-623 UBERON:0027368 denotes matrix
T20 624-649 D020778 denotes metalloproteinase (MMP)-2
T25 643-649 PR:P08253 denotes MMP)-2
T26 643-649 Q9GLE5 denotes MMP)-2
T27 643-649 P08253 denotes MMP)-2
T28 643-649 Q90611 denotes MMP)-2
T30 643-649 PR:Q8MPP3 denotes MMP)-2
T31 643-649 P33436 denotes MMP)-2
T32 643-649 PR:Q90611 denotes MMP)-2
T33 643-649 PR:P33436 denotes MMP)-2
T34 643-649 PR:000010479 denotes MMP)-2
T35 643-649 PR:P33434 denotes MMP)-2
T36 643-649 P33434 denotes MMP)-2
T37 643-649 P50757 denotes MMP)-2
T29 643-649 GO:0004228 denotes MMP)-2
T38 669-673 10118 denotes Rats
T39 669-673 10116 denotes Rats
T40 669-673 D051381 denotes Rats
T42 708-730 UBERON:0001627 denotes middle cerebral artery
T43 708-740 D020244 denotes middle cerebral artery occlusion
T44 708-740 D020244 denotes middle cerebral artery occlusion
T49 763-766 CVCL_E777 denotes min
T50 805-812 CHEBI:52071 denotes dextran
T51 805-812 D003911 denotes dextran
T52 805-812 D003911 denotes dextran
T53 816-819 UBERON:0000120 denotes BBB
T54 847-853 UBERON:0000479 denotes tissue
T55 854-864 D007238 denotes infarction
T56 854-864 D007238 denotes infarction
T59 903-932 C009591 denotes triphenyltetrazolium chloride
T60 903-932 C009591 denotes triphenyltetrazolium chloride
T61 903-932 CHEBI:9743 denotes triphenyltetrazolium chloride
T62 903-932 CHEBI:78019 denotes triphenyltetrazolium chloride
T64 961-964 Q03701 denotes CBF
T65 961-964 PR:O97101 denotes CBF
T66 961-964 PR:000005312 denotes CBF
T67 961-964 P53569 denotes CBF
T68 1010-1013 CHEBI:340824 denotes MMP
T71 1010-1013 CHEBI:59761 denotes MMP
T72 1010-1015 PR:P08253 denotes MMP-2
T73 1010-1015 Q9GLE5 denotes MMP-2
T74 1010-1015 P08253 denotes MMP-2
T75 1010-1015 Q90611 denotes MMP-2
T77 1010-1015 PR:Q8MPP3 denotes MMP-2
T78 1010-1015 P33436 denotes MMP-2
T79 1010-1015 PR:Q90611 denotes MMP-2
T80 1010-1015 PR:P33436 denotes MMP-2
T81 1010-1015 PR:000010479 denotes MMP-2
T82 1010-1015 PR:P33434 denotes MMP-2
T83 1010-1015 P33434 denotes MMP-2
T84 1010-1015 P50757 denotes MMP-2
T76 1010-1015 GO:0004228 denotes MMP-2
T85 1079-1086 CHEBI:52071 denotes dextran
T86 1079-1086 D003911 denotes dextran
T87 1079-1086 D003911 denotes dextran
T88 1133-1141 UBERON:0002435 denotes striatum
T89 1133-1141 UBERON:0005383 denotes striatum
T90 1150-1163 UBERON:0001928 denotes preoptic area
T91 1182-1185 Q03701 denotes CBF
T92 1182-1185 PR:O97101 denotes CBF
T93 1182-1185 PR:000005312 denotes CBF
T94 1182-1185 P53569 denotes CBF
T95 1186-1195 MOP:0000569 denotes reduction
T97 1219-1222 P60254 denotes MCA
T96 1219-1222 CHEBI:34342 denotes MCA
T98 1245-1251 UBERON:0001851 denotes cortex
T99 1333-1341 CHEBI:52071 denotes dextrans
T100 1333-1341 D003911 denotes dextrans
T101 1333-1341 D003911 denotes dextrans
T102 1402-1405 UBERON:0000120 denotes BBB
T103 1414-1420 UBERON:0000479 denotes tissue

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 119-326 DRI_Outcome denotes Blood brain barrier (BBB) damage that occurs within the thrombolytic time window is increasingly appreciated to negatively impact the safety and efficacy profiles of thrombolytic therapy for ischemic stroke.
T2 327-451 DRI_Challenge denotes However, the spatiotemporal evolution of BBB damage in this early stroke stage and the underlying mechanisms remain unclear.
T3 452-668 DRI_Approach denotes Here, we investigated the topographical distribution of BBB damage and its association with tissue injury within the first 3 h after ischemia onset and the roles of matrix metalloproteinase (MMP)-2/9 in this process.
T4 669-840 DRI_Background denotes Rats were subjected to 1, 2, or 3 h of middle cerebral artery occlusion (MCAO) followed by 10 min reperfusion with fluorescence-labeled dextran as BBB permeability marker.
T5 841-939 DRI_Background denotes Acute tissue infarction was evidenced by staining defect with triphenyltetrazolium chloride (TTC).
T6 940-1009 DRI_Background denotes Cerebral blood flow (CBF) was measured by magnetic resonance imaging.
T7 1010-1062 DRI_Background denotes MMP-2/9 were assessed by gel and in situ zymography.
T8 1268-1386 DRI_Background denotes Interestingly, high (2000 kDa) and low (70 kDa) molecular weight dextrans displayed almost identical leakage patterns.
T9 1387-1548 DRI_Outcome denotes Different from BBB damage, tissue infarction was first seen in the ischemic dorsal striatum and the parietal/insular cortex which experienced ~90% CBF reduction.
T10 1549-1690 DRI_Background denotes Increased gelatinolytic activity colocalized with dextran leakage, and MMP-2 was found to be the major enzymatic source on gelatin zymograms.
T11 1691-1786 DRI_Approach denotes Pretreatment with MMP inhibitor GM6001 significantly reduced dextran leakage induced by 2-h and
T12 1795-1796 DRI_Approach denotes .
T13 1797-1963 DRI_Outcome denotes Taken together, our findings reveal substantial differences in the topographic distribution of BBB damage and tissue infarction within the first 3 h after MCAO onset.
T14 1964-2140 DRI_Challenge denotes Unlike ischemic neuronal damage, BBB damage appears to develop faster in brain regions with moderately severe ischemia, and MMP-2 contributes to this early ischemic BBB damage.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 310-325 HP_0002140 denotes ischemic stroke
T2 319-325 HP_0001297 denotes stroke
T3 393-399 HP_0001297 denotes stroke

Allie

Id Subject Object Predicate Lexical cue
SS1_22813865_1_0 119-138 expanded denotes Blood brain barrier
SS2_22813865_1_0 140-143 abbr denotes BBB
SS1_22813865_3_0 617-641 expanded denotes matrix metalloproteinase
SS2_22813865_3_0 643-646 abbr denotes MMP
SS1_22813865_4_0 708-740 expanded denotes middle cerebral artery occlusion
SS2_22813865_4_0 742-746 abbr denotes MCAO
SS1_22813865_5_0 903-932 expanded denotes triphenyltetrazolium chloride
SS2_22813865_5_0 934-937 abbr denotes TTC
SS1_22813865_6_0 940-959 expanded denotes Cerebral blood flow
SS2_22813865_6_0 961-964 abbr denotes CBF
AE1_22813865_1_0 SS1_22813865_1_0 SS2_22813865_1_0 abbreviatedTo Blood brain barrier,BBB
AE1_22813865_3_0 SS1_22813865_3_0 SS2_22813865_3_0 abbreviatedTo matrix metalloproteinase,MMP
AE1_22813865_4_0 SS1_22813865_4_0 SS2_22813865_4_0 abbreviatedTo middle cerebral artery occlusion,MCAO
AE1_22813865_5_0 SS1_22813865_5_0 SS2_22813865_5_0 abbreviatedTo triphenyltetrazolium chloride,TTC
AE1_22813865_6_0 SS1_22813865_6_0 SS2_22813865_6_0 abbreviatedTo Cerebral blood flow,CBF

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-118 DRI_Challenge denotes Spatiotemporal evolution of blood brain barrier damage and tissue infarction within the first 3h after ischemia onset.
T2 119-326 DRI_Outcome denotes Blood brain barrier (BBB) damage that occurs within the thrombolytic time window is increasingly appreciated to negatively impact the safety and efficacy profiles of thrombolytic therapy for ischemic stroke.
T3 327-451 DRI_Challenge denotes However, the spatiotemporal evolution of BBB damage in this early stroke stage and the underlying mechanisms remain unclear.
T4 452-668 DRI_Approach denotes Here, we investigated the topographical distribution of BBB damage and its association with tissue injury within the first 3 h after ischemia onset and the roles of matrix metalloproteinase (MMP)-2/9 in this process.
T5 669-840 DRI_Background denotes Rats were subjected to 1, 2, or 3 h of middle cerebral artery occlusion (MCAO) followed by 10 min reperfusion with fluorescence-labeled dextran as BBB permeability marker.
T6 841-939 DRI_Background denotes Acute tissue infarction was evidenced by staining defect with triphenyltetrazolium chloride (TTC).
T7 940-1009 DRI_Background denotes Cerebral blood flow (CBF) was measured by magnetic resonance imaging.
T8 1010-1062 DRI_Background denotes MMP-2/9 were assessed by gel and in situ zymography.
T9 1063-1068 DRI_Unspecified denotes After
T10 1069-1077 Token_Label.OUTSIDE denotes 2-h MCAO
T11 1077-1257 DRI_Unspecified denotes , dextran leakage was seen in the ischemic ventromedial striatum and the preoptic area which showed ~70% CBF reduction, and expanded to other MCA regions including the cortex after
T12 1258-1266 Token_Label.OUTSIDE denotes 3-h MCAO
T13 1266-1267 DRI_Unspecified denotes .
T14 1268-1386 DRI_Background denotes Interestingly, high (2000 kDa) and low (70 kDa) molecular weight dextrans displayed almost identical leakage patterns.
T15 1387-1548 DRI_Outcome denotes Different from BBB damage, tissue infarction was first seen in the ischemic dorsal striatum and the parietal/insular cortex which experienced ~90% CBF reduction.
T16 1549-1690 DRI_Background denotes Increased gelatinolytic activity colocalized with dextran leakage, and MMP-2 was found to be the major enzymatic source on gelatin zymograms.
T17 1691-1786 DRI_Approach denotes Pretreatment with MMP inhibitor GM6001 significantly reduced dextran leakage induced by 2-h and
T18 1787-1795 Token_Label.OUTSIDE denotes 3-h MCAO
T19 1795-1796 DRI_Approach denotes .
T20 1797-1963 DRI_Outcome denotes Taken together, our findings reveal substantial differences in the topographic distribution of BBB damage and tissue infarction within the first 3 h after MCAO onset.
T21 1964-2140 DRI_Challenge denotes Unlike ischemic neuronal damage, BBB damage appears to develop faster in brain regions with moderately severe ischemia, and MMP-2 contributes to this early ischemic BBB damage.